By Sabela Ojea Esperion Therapeutics and Daiichi Sankyo Europe GmbH said they have settled their pending commercial litigation and agreed on a $125 million.
Pharmaceutical stocks have generally fallen, partly because of regulatory concerns, but also because high interest rates have made the companies dividends.
Nestle’s real internal growth in the third quarter showed a sequential underlying improvement in volume trends, Citi said, adding the RIG consensus miss was small, and “should leave 2023 consensus expectations pretty much unchanged.”
By Christian Moess Laursen AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following positive test.
By Anthony O. Goriainoff AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment with or.